TITLE

Hypotension caused by L-dopa

AUTHOR(S)
Shanks, R G
PUB. DATE
August 1970
SOURCE
British Medical Journal;8/15/1970, Vol. 3 Issue 5719, p403
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64097689

 

Related Articles

  • Just Visiting. Lantos, John D. // Hastings Center Report;May/Jun2004, Vol. 34 Issue 3, p6 

    Presents an article on dealing with a physician who advocates do-not-resuscitate orders. Role of Parkinson's disease in the incidence of orthostatic hypotension; Effect of L-Dopa on the treatment; Background on the use of a ventilator in treating the patient.

  • Hypotension: The other side of the coin. Trottier, Dee; Kochar, Mahendr; Lippman, Helen // RN;Mar91, Vol. 54 Issue 3, p38 

    Provides guidelines that will help nurses deal with hypotensive patients. Causes of hypotension; Procedure for assessing patients at risk of the disease; Treatment for the condition.

  • Protective Effects of L-Dopa and Carbidopa Combined Treatments on Human Catecholaminergic Cells. Colamartino, Monica; Padua, Luca; Meneghini, Carlo; Leone, Stefano; Cornetta, Tommaso; Testa, Antonella; Cozzi, Renata // DNA & Cell Biology;Nov2012, Vol. 31 Issue 11, p1572 

    Parkinson's disease (PD) is one of the most common neurodegenerative disorders characterized by decreased levels of the neurotransmitter dopamine (DA) in the striatum of the brain, as a result of degeneration of DA neurons. Levodopa (L-Dopa) crosses the blood-brain barrier and its administration...

  • Causes of chronic orthostatic hypotension. Smith, Jeanette M.; Chi-Lum, Bonnie // JAMA: Journal of the American Medical Association;9/28/94, Vol. 272 Issue 12, p906d 

    Presents an abstract determining the frequency of various causes of orthostatic hypotension. Characteristics of subject respondents chosen for survey; Effect of antidepressant drugs on orthostatic hypotension.

  • Treating postural hypotension. Watson, R.D.S. // British Medical Journal (Clinical Research Edition);2/14/1987, Vol. 294 Issue 6569, p390 

    Focuses on the treatment of postural hypotension. Integrity of the autonomic nervous system; Causes of the hypotension; Effect of patients with autonomic failure on fluid and electrolyte homeostasis.

  • L-Dopa for Parkinson's.  // Time;10/4/1968, Vol. 92 Issue 14, p86 

    The article focuses on the potential of the new drug Levo-dihydroxyphenylalanine or L-dopa as treatment for Parkinson's disease. It states that L-Dopa is an amino acid that crosses the barrier between the bloodstream and the brain, and breaks down to yield dopamine in the brain. It also mentions...

  • Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease. A H Evans // Journal of Neurology, Neurosurgery & Psychiatry;Mar2009, Vol. 80 Issue 3, p267 

    BACKGROUND: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acute challenges with dopaminergic drugs, L-dopa and methylphenidate, and cause cross sensitisation. METHODS: The mood, psychomotor and reward potentiating effects of an acute challenge with...

  • Pharmacokinetics of L-dopa: Special reference to food and aging. Miho Murata // Journal of Neurology;Aug2006 Supplement 3, Vol. 253, p47 

    According to our data in rats, peripheral 3.4-dihydroxyphenylalanine (DOPA) kinetics are similar to striatal DOPA and dopamine kinetics. The measurement of plasma l-3.4-dihydroxyphenylalanine (L-dopa) concentration is thus useful to predict dopamine kinetics in the striatum and to treat the...

  • Parkinson's disease: carbidopa, nausea, and dyskinesia. Hinz, Marty; Stein, Alvin; Cole, Ted // Clinical Pharmacology;2014, Vol. 6, p189 

    When L-dopa use began in the early 1960s for the treatment of Parkinson's disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to L-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been...

  • Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. Meltzer, Herbert .Y; Mills, Roger; Revell, Stephen; Williams, Hilde; Johnson, Ann; Bahr, Daun; Friedman, Joseph H. // Neuropsychopharmacology;Mar2010, Vol. 35 Issue 4, p881 

    Psychotic symptoms occur in up to 40% of patients with Parkinson's disease (PD). Clozapine and quetiapine, two atypical antipsychotic drugs, at doses markedly lower than those effective in schizophrenia, which, nevertheless, still cause sedation, hypotension, and other side effects, are widely...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics